Key result
Serum from patients with alcoholic liver cirrhosis reduced human coronary artery smooth muscle cell proliferation and migration compared to healthy control serum (p < 0.05).
Why the study?
Liver cirrhosis is associated with increased coronary artery disease risk and complications post-PCI, leading to the hypothesis that cirrhosis influences post-PCI intimal hyperplasia.
Does serum from patients with severe alcoholic liver cirrhosis inhibit proliferation and migration of human coronary artery smooth muscle cells?
Does serum from patients with severe alcoholic liver cirrhosis inhibit proliferation and migration of human coronary artery smooth muscle cells?
Serum from patients with severe alcoholic liver cirrhosis contains circulating factors that inhibit coronary smooth muscle cell growth, potentially affecting clinical outcomes like intimal hyperplasia after PCI.
May suggest reduced intimal hyperplasia risk post-PCI in alcoholic cirrhosis; hypothesis-generating, requires in vivo validation.
Liver cirrhosis has been associated with an increased risk of coronary artery disease and clinical complications following percutaneous coronary revascularization. The present study is based on the hypothesis that cirrhosis may influence intimal hyperplasia following PCI. Sera from 10 patients with alcoholic liver cirrhosis and 10 age-matched healthy controls were used to stimulate cultured human coronary artery smooth muscle cells (HCASMC) for 48 h. HCASMC proliferation, migration, gene expression and apoptosis were investigated. Serum concentrations of growth factors and markers of liver function were also determined in patients and healthy controls. Treatment of HCASMC with patient sera reduced cell proliferation and migration (p < 0.05 vs. healthy controls), whereas apoptosis was unaffected (p = 0.160). Expression of genes associated with a synthetic vascular smooth muscle cell phenotype was decreased in cells stimulated with serum from cirrhotic patients (RBP1, p = 0.001; SPP1, p = 0.003; KLF4, p = 0.004). Platelet-derived growth factor-BB serum concentrations were lower in patients (p = 0.001 vs. controls). The results suggest the presence of circulating factors in patients with alcoholic liver cirrhosis affecting coronary smooth muscle cell growth. These findings may have implications for clinical outcomes following percutaneous coronary revascularization in these patients.
No takes yet. Share an insight, caveat, or question.
Mechelinck et al. (2021) studied Alcoholic liver cirrhosis (n=20). Serum from patients with alcoholic liver cirrhosis vs. Serum from age-matched healthy controls was evaluated on HCASMC proliferation and migration (p=<0.05). Serum from patients with alcoholic liver cirrhosis reduced human coronary artery smooth muscle cell proliferation and migration compared to healthy control serum (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: